Advanced-Stage Mycosis Fungoides and Sézary Syndrome: Survival and Response to Treatment

Conclusion We found that only a few factors can predict OS and DSS for patients with advanced MF/SS. Also, nonchemotherapy options should be preferred for front-line therapy to improve survival, outcomes, and side effects, including immunosuppression. Micro-Abstract Prognostic factors would be helpful to select patients with advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) for nonaggressive versus aggressive therapy. In 168 patients with advanced-stage MF/SS, skin stage, nodal involvement, age > 65 years, high lactate dehydrogenase, and histologic large cell transformation were associated with worse overall survival. Multiagent chemotherapy should be limited to patients with refractory, progressive disease.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research